The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects

Neuropharmacology

Volumn 60, Issue 2-3, 2011, Pages 244-251

  Kinsey, Steven G ^a   Mahadevan, Anu ^b   Zhao, Bingjun ^b   Sun, Hang ^b   Naidu, Pattipati S ^a   Razdan, Raj K ^b   Selley, Dana E ^a   Imad Damaj, M ^a   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ORGANIX INC   (United States)

Author keywords

CB1; CB2; Endogenous cannabinoid agonist; Inflammation; Lipopolysaccharide induced edema; Neuropathic pain

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR AGONIST; LIPOPOLYSACCHARIDE; O 3223; RIMONABANT; UNCLASSIFIED DRUG; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; CANNABINOID; CANNABINOID 2 RECEPTOR; CYCLOHEXANOL DERIVATIVE; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPERALGESIA; INFLAMMATION; MALE; MOUSE; NERVE COMPRESSION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG POTENTIATION; METABOLISM; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANIMALS; CANNABINOIDS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFLAMMATION; MALE; MICE; PAIN; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 78650807828     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.09.004     Document Type: Article

References (40)

1. U. Anand, W.R. Otto, D. Sanchez-Herrera, P. Facer, Y. Yiangou, Y. Korchev, R. Birch, C. Benham, C. Bountra, I.P. Chessell, and P. Anand Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons Pain 138 2008 667 680
2. J.B. Braden, and M.D. Sullivan Suicidal thoughts and behavior among adults with self-reported pain conditions in the national comorbidity survey replication J. Pain 9 2008 1106 1115
3. G.A. Cabral, and L. Griffin-Thomas Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation Expert. Rev. Mol. Med. 11 2009 e3
4. N. Clayton, F.H. Marshall, C. Bountra, and C.T. O'Shaughnessy CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain Pain 96 2002 253 260
5. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, and A.H. Lichtman Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. U.S.A. 98 2001 9371 9376
6. P.J. Crocker, B. Saha, W.J. Ryan, J.L. Wiley, B.R. Martin, R.A. Ross, R.G. Pertwee, and R.K. Razdan Development of agonists, partial agonists and antagonists in the Delta(8)-tetrahydrocannabinol series Tetrahedron 55 1999 13907 13926
7. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
8. S. Galiegue, S. Mary, J. Marchand, D. Dussossoy, D. Carriere, P. Carayon, M. Bouaboula, D. Shire, G. Le Fur, and P. Casellas Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur. J. Biochem. 232 1995 54 61
9. J. Gertsch, M. Leonti, S. Raduner, I. Racz, J.Z. Chen, X.Q. Xie, K.H. Altmann, M. Karsak, and A. Zimmer Beta-caryophyllene is a dietary cannabinoid Proc. Natl. Acad. Sci. U.S.A. 105 2008 9099 9104
10. J. Guindon, and A.G. Hohmann Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain Br. J. Pharmacol. 153 2008 319 334
11. T. Gutierrez, J.N. Farthing, A.M. Zvonok, A. Makriyannis, and A.G. Hohmann Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis Br. J. Pharmacol. 150 2007 153 163
12. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, R.G. Pertwee, R.A. Ross, R. Mechoulam, and E. Fride HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. U.S.A. 96 1999 14228 14233
13. M.M. Ibrahim, F. Porreca, J. Lai, P.J. Albrecht, F.L. Rice, A. Khodorova, G. Davar, A. Makriyannis, T.W. Vanderah, H.P. Mata, and T.P. Malan Jr. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids Proc. Natl. Acad. Sci. U.S.A. 102 2005 3093 3098
14. M.M. Ibrahim, M.L. Rude, N.J. Stagg, H.P. Mata, J. Lai, T.W. Vanderah, F. Porreca, N.E. Buckley, A. Makriyannis, and T.P. Malan Jr. CB2 cannabinoid receptor mediation of antinociception Pain 122 2006 36 42
15. S.A. Kanaan, N.E. Saade, J.J. Haddad, A.M. Abdelnoor, S.F. Atweh, S.J. Jabbur, and B. Safieh-Garabedian Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain Pain 66 1996 373 379
16. S.G. Kinsey, J.Z. Long, S.T. O'Neal, R.A. Abdullah, J.L. Poklis, D.L. Boger, B.F. Cravatt, and A.H. Lichtman Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain J. Pharmacol. Experim. Therapeut. 330 2009 902 910
17. N.M. Kogan, and R. Mechoulam Cannabinoids in health and disease Dialogues Clin. Neurosci. 9 2007 413 430
18. A.H. Lichtman, C.C. Shelton, T. Advani, and B.F. Cravatt Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia Pain 109 2004 319 327
19. P.J. Little, D.R. Compton, M.R. Johnson, L.S. Melvin, and B.R. Martin Pharmacology and stereoselectivity of structurally novel cannabinoids in mice J. Pharmacol. Exp. Ther. 247 1988 1046 1051
20. K. Mackie Cannabinoid receptors as therapeutic targets Annu. Rev. Pharmacol. Toxicol. 46 2006 101 122
21. T.P. Malan Jr., M.M. Ibrahim, H. Deng, Q. Liu, H.P. Mata, T. Vanderah, F. Porreca, and A. Makriyannis CB2 cannabinoid receptor-mediated peripheral antinociception Pain 93 2001 239 245
22. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, and D.R. Compton Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 50 1995 83 90
23. A.G. Nackley, A. Makriyannis, and A.G. Hohmann Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation Neuroscience 119 2003 747 757
24. S. Ohtori, K. Takahashi, H. Moriya, and R.R. Myers TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord Spine 29 2004 1082 1088 (Phila Pa 1976)
25. J. Palazuelos, T. Aguado, M.R. Pazos, B. Julien, C. Carrasco, E. Resel, O. Sagredo, C. Benito, J. Romero, I. Azcoitia, J. Fernandez-Ruiz, M. Guzman, and I. Galve-Roperh Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity Brain 132 2009 3152 3164
26. S.N. Pattipati, S.G. Kinsey, T. Guo, B.F. Cravatt, and A.H. Lichtman Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase (FAAH) J. Pharmacol. Experim. Therapeut. 334 2010 182 190
27. E.J. Rahn, A.M. Zvonok, A. Makriyannis, and A.G. Hohmann Antinociceptive effects of racemic AM1241 an d its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation AAPS J. 12 2010 147 157
28. R. Russo, J. Loverme, G. La Rana, T.R. Compton, J. Parrott, A. Duranti, A. Tontini, M. Mor, G. Tarzia, A. Calignano, and D. Piomelli The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl- 3-yl ester) reduces neuropathic pain after oral administration in mice J. Pharmacol. Experim. Therapeut. 322 2007 236 242
29. N.M. Sain, A. Liang, S.A. Kane, and M.O. Urban Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain Neuropharmacology 57 2009 235 241
30. H. Sun, A. Mahadevan, and R.K. Razdan A novel methodology for the synthesis of 1-desoxy-Delta(8)-tetrahydrocannabinol (THC) analogues Tetrahed. Lett. 45 2004 615 617
31. A. Tjolsen, O.G. Berge, S. Hunskaar, J.H. Rosland, and K. Hole The formalin test: an evaluation of the method Pain 51 1992 5 17
32. K.J. Valenzano, L. Tafesse, G. Lee, J.E. Harrison, J.M. Boulet, S.L. Gottshall, L. Mark, M.S. Pearson, W. Miller, S. Shan, L. Rabadi, Y. Rotshteyn, S.M. Chaffer, P.I. Turchin, D.A. Elsemore, M. Toth, L. Koetzner, and G.T. Whiteside Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy Neuropharmacology 48 2005 658 672
33. M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis, D. Piomelli, J.S. Davison, L.J. Marnett, V. Di Marzo, Q.J. Pittman, K.D. Patel, and K.A. Sharkey Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 310 2005 329 332
34. L.R. Watkins, M.R. Hutchinson, A. Ledeboer, J. Wieseler-Frank, E.D. Milligan, and S.F. Maier Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids Brain Behav. Immun. 21 2007 131 146
35. G. Wotherspoon, A. Fox, P. McIntyre, S. Colley, S. Bevan, and J. Winter Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons Neuroscience 135 2005 235 245
36. W. Yamamoto, T. Mikami, and H. Iwamura Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain Eur. J. Pharmacol. 583 2008 56 61
37. B.B. Yao, G. Hsieh, A.V. Daza, Y. Fan, G.K. Grayson, T.R. Garrison, O. El Kouhen, B.A. Hooker, M. Pai, E.J. Wensink, A.K. Salyers, P. Chandran, C.Z. Zhu, C. Zhong, K. Ryther, M.E. Gallagher, C.L. Chin, A.E. Tovcimak, V.P. Hradil, G.B. Fox, M.J. Dart, P. Honore, and M.D. Meyer Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl- cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)- ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging J. Pharmacol. Experim. Therapeut. 328 2009 141 151
38. B.B. Yao, G.C. Hsieh, J.M. Frost, Y. Fan, T.R. Garrison, A.V. Daza, G.K. Grayson, C.Z. Zhu, M. Pai, P. Chandran, A.K. Salyers, E.J. Wensink, P. Honore, J.P. Sullivan, M.J. Dart, and M.D. Meyer In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models Br. J. Pharmacol. 153 2008 390 401
39. B.B. Yao, S. Mukherjee, Y. Fan, T.R. Garrison, A.V. Daza, G.K. Grayson, B.A. Hooker, M.J. Dart, J.P. Sullivan, and M.D. Meyer In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br. J. Pharmacol. 149 2006 145 154
40. J. Zhang, C. Hoffert, H.K. Vu, T. Groblewski, S. Ahmad, and D. O'Donnell Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models Eur. J. Neurosci. 17 2003 2750 2754